Xywav is an approved drug owned by Jazz Pharmaceuticals. It contains a mixture of sodium, potassium, magnesium, and calcium salts of ghb. Its authorization for market use was given on 21 July, 2020 and is available in oral solution dosage form.
The generic versions of Xywav are set to be available after 19 September, 2037. Xywav currently holds 21 drug patents and out of those, 2 have already expired.
Xywav is typically used for the treatment of cataplexy or excessive daytime sleepiness (eds) in patients who are at least 7 years old with narcolepsy. Its unique mixture of sodium, potassium, magnesium, and calcium salts of ghb is administered between 2 and 4 hours after eating. It's also utilized in methods treating patients with a prescription drug using a computer database in a computer system for distribution. Furthermore, it's effective in reducing adverse effects in patients who are suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium.
Xywav holds a significant number of patents, of which the expiration date of the last patent is 19 September, 2037. Keep in mind, the generics of Xywav will probably be released after this date. Below are the details of the patent: